Advanced Search

 

Study ID Status Title Patient Level Data
100290 Completed A phase IIIB/IV, open-label, multi-center trial to evaluate the safety, tolerability, and efficiency of HIV-1 infected subjects switching their current protease-inhibitor therapies for a fosamprenavir therapy over 48 weeks Study Listed on ClinicalStudyDataRequest.com
100327 Completed A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) BID vs Combivir (lamivudine 150mg and zidovudine 300mg) BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks Study Listed on ClinicalStudyDataRequest.com
100732 Completed A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks Study Listed on ClinicalStudyDataRequest.com
101822 Completed A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) Study Listed on ClinicalStudyDataRequest.com
102577 Completed A Phase I, Open-Label, 2-Period, Single-Sequence, Drug Interaction Study to Assess Steady-State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD with Fosamprenavir 700mg BID + RTV 100mg BID in Opiate-Dependent, HIV Seronegative, Adult Subjects
104807 Completed Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) – Pharmacokinetic Study in HIV-Infected Patients –
109477 Completed Prospective epidemiological study of the prevalence of HLAB*5701 in HIV-1 infected patients
111405 Completed A Phase I, open label, randomized, two period, one-way two sequence crossover study to evaluate the effect of darunavir/ritonavir and lopinavir/ritonavir on GSK1349572 pharmacokinetics in healthy adult subjects (ING111405).
111451 Completed A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected with HIV
111521 Completed A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521) Study Listed on ClinicalStudyDataRequest.com
111602 Completed A Phase I, open label, randomized, four-period crossover studyto evaluate the effects of Maalox® Advanced Maximum Strengthand One A Day® Maximum on pharmacokinetics of GSK1349572in healthy adult subjects
111603 Completed A Phase I, open label, two period, single fixed-sequence crossover study to evaluate the effect of etravirine on GSK1349572 pharmacokinetics in healthy adult subjects (ING111603)
111604 Completed A Phase I, Open Label, Single Sequence,Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604)
111762 Active, not recruiting A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults Study Listed on ClinicalStudyDataRequest.com
111839 Completed A Phase I, open label crossover study to evaluate the effect of etravirine on GSK1265744 pharmacokinetics in healthy adult subjects
111853 Completed An Open Label, Non-Randomized, Single dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853)
111854 Completed Phase I, Open Label, Randomized, Drug-Drug Interaction Study in Healthy Subjects to Investigate the Effects of Co-administered Atazanavir/Ritonavir (300mg/100mg) or Atazanavir 400mg Administered Once Daily on the Steady-State Plasma Pharmacokinetics of GSK1349572 30mg Administered Once Daily
111855 Completed A Double-Blind study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol when Co-administered with Dolutegravir in Healthy Adult Female Subjects
111856 Completed A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856).
111950 Completed Fractures over time stratified by HIV infection and Antiretroviral Therapy (ART) exposure
112276 Completed A Phase IIb study to select a once daily dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naive adult subjects Study Listed on ClinicalStudyDataRequest.com
112334 Completed Drug Use Investigation for Lexiva tablet (HRD Cooperative Investigation)
112346 Completed Special Drug Use Investigation for Lexiva tablet (Pregnancy) (HRD Cooperative Investigation)
112348 Completed Special Drug Use Investigation for EPZICOM® (abacavir sulfate/lamivudine) tablet (Pregnancy) (HRD Cooperative Investigation)
112574 Completed A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen. Study Listed on ClinicalStudyDataRequest.com